Trinity Biotech swings to profit as HIV test order signals recovery
Compartilhar
Trinity Biotech (NASDAQ:TRIB) shares are in focus after the diagnostics specialist reported a return to positive adjusted EBITDA and secured a major 9 million-unit order for its flagship HIV screening product.
